SELECT COUNTRY

VIEW ALL
AFRICA
AMERICAS
ASIA
EUROPE
OCEANIA

MALI: LATEST INTERVIEWS MORE INTERVIEWS

Mark Bristow
PRESIDENT & CEO, BARRICK GOLD
"Our successful exploration programs are feeding high-quality prospects into an already bulging pipeline and we expect to grow our reserves net of depletion again this year."
Mining
Canada
United States
Zambia
DRC
Mali
Dominican Republic
MACIG
Larry Phillips
CEO, COMPASS GOLD
Compass Gold explains progress at its Sikasso property in Mali.
Mining
Mali
MACIG
Bert Monro
CEO, CORA GOLD
West African junior Cora Gold updates GBR on progress at Sanankoro, Mali.
Mining
Mali
MACIG
Nana Sangmuah
CEO, ROSCAN GOLD
"Sandwiched between two of the largest producing assets in West Africa and with our six discoveries made already, we hope to join the league of tier-one mines."
Mining
Mali
MACIG

MALI: LATEST ARTICLES

Mining
Cote d’Ivoire
Mali
Ghana
Burkina Faso
MACIG

Expanding Mining Frontiers in West Africa

October 02, 2020
The under-explored gold-bearing grounds of West Africa are the “last frontier” in the gold space.
Mining
South Africa
Zimbabwe
Tanzania
Mali
Mozambique
Kenya
MACIG

The Delicate Balancing Act of Developing ‘Vogue Minerals’ Projects

February 05, 2019
THE OFFICIAL MINING IN AFRICA COUNTRY INVESTMENT GUIDE (MACIG) 2019
Expert Opinion Article contributed by SRK Consulting’s global team of consultants.
Mining
Guinea
Cote d’Ivoire
Mali
Ghana
Burkina Faso
MACIG

Prospective Lands: West Africa’s Mining Potential

November 15, 2018
MACIG 2019 West Africa Pre-Release Edition
GBR examines the current excitement surrounding the West African mining potential.
MORE ARTICLES

MALI: RECENTLY RELEASED PUBLICATIONS

MACIG 2023 - Mining in Africa Country Investment Guide

January 30, 2023

MACIG 2023 Pre-Release

November 21, 2022

MACIG 2022

April 19, 2022

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENTLY PUBLISHED

United States Life Sciences 2023

In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
MORE PREVIOUSLY PUBLISHED

PARTNER EVENTS

SEE ALL